Drug Profile


Alternative Names: Anti-PD-L1 monoclonal antibody; Anti-PD-LI mAb; Anti-programmed cell death 1 ligand 1 monoclonal antibody; MEDI-4736

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator MedImmune
  • Developer Advaxis; AstraZeneca; Canadian Cancer Trials Group; Celgene International SARL; Centre Leon Berard; Childrens Hospital Los Angeles; Eli Lilly; GlaxoSmithKline; Gradalis; Immunocore; Juno Therapeutics; Kyoto Breast Cancer Research Network; Ludwig Institute for Cancer Research; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; Mirati Therapeutics; National Cancer Institute (USA); Northwestern University; Pharmacyclics; Plexxikon; Swiss Group for Clinical Cancer Research; University of Texas M. D. Anderson Cancer Center; VentiRx Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bladder cancer
  • Phase III Head and neck cancer; Non-small cell lung cancer
  • Phase II/III Breast cancer; Pancreatic cancer
  • Phase II Acute myeloid leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Prostate cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Fallopian tube cancer; Lymphoma; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
  • Phase I CNS cancer; Myelofibrosis; Non-Hodgkin's lymphoma
  • Clinical Phase Unknown Renal cell carcinoma
  • Phase Unknown Cutaneous T cell lymphoma; Peripheral T-cell lymphoma

Most Recent Events

  • 22 Feb 2017 Canadian Cancer Trials Group plans a phase II trial for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Combination therapy) (NCT03057106)
  • 17 Feb 2017 Updated efficacy and adverse events data from a phase I/II trial in Urogenital cancer released by AstraZeneca
  • 17 Feb 2017 Celgene and Singapore General Hospital plan a phase II trial for T-cell lymphoma (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in Singapore (NCT03054532)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top